- Home
- PCN vs PHAT Comparison
PCN vs PHAT Comparison
Compare PCN & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCN | PHAT |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 862.7M | 894.0M |
| IPO Year | 2001 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PCN | PHAT |
|---|---|---|
| Price | $11.82 | $9.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.83 |
| AVG Volume (30 Days) | 298.8K | ★ 1.2M |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | N/A | $93.04 |
| Revenue Next Year | N/A | $58.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $11.40 | $4.25 |
| 52 Week High | $13.49 | $18.31 |
Technical Indicators
Market Signals| Indicator | PCN | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 47.19 | 31.78 |
| Support Level | $11.45 | N/A |
| Resistance Level | $12.15 | $12.83 |
| Average True Range (ATR) | 0.11 | 0.72 |
| MACD | 0.01 | -0.26 |
| Stochastic Oscillator | 65.66 | 2.57 |
Price Performance
Historical ComparisonAbout PCN Pimco Corporate & Income Strategy Fund
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.